Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Tonix Pharmaceuticals, Inc. clinical trials
The registry lists 34 studies whose lead sponsor is Tonix Pharmaceuticals, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Keep track of what changes. Save the Tonix Pharmaceuticals, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Tonix Pharmaceuticals, Inc..
- Tonix Pharmaceuticals, Inc.34 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 34 of 34.
- A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)RecruitingNCT07621237Phase 2
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy SubjectsCompletedNCT07473752Phase 1
- A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese SubjectsCompletedNCT07464535Phase 1
- A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly ParticipantsActive, not recruitingNCT07413367Phase 1
- Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)TerminatedNCT06045793Phase 2
- A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic MigraineCompletedNCT05679908Phase 2
- Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With FibromyalgiaTerminatedNCT02829814Phase 3
- A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia PatientsCompletedNCT02589275Phase 3
- Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)CompletedNCT05686408Phase 2
- A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgiaCompletedNCT02436096Phase 3
- A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSDTerminatedNCT03841773Phase 3
- Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related ConditionsCompletedNCT02421679Phase 2
- 12-Week Open-Label Extension Study of TNX-102 SL in PTSD PatientsTerminatedNCT03110575Phase 3
- A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSDCompletedNCT03508700Phase 3
- A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With FibromyalgiaCompletedNCT05273749Phase 3
- A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 InfectionCompletedNCT05472090Phase 2
- Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide AntigensTerminatedNCT05216510Phase 1
- Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related ConditionsCompletedNCT02277704Phase 2
- Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSDTerminatedNCT03062540Phase 3
- A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaCompletedNCT04508621Phase 3
- Safety and Efficacy Study of TNX-102 SL in Participants With PTSDWithdrawnNCT05372887Phase 2
- A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaCompletedNCT04172831Phase 3
- An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) SubjectsWithdrawnNCT04996056Phase 2
- Dose-Proportionality and Food Effect Study of TNX-102 SLCompletedNCT04164719Phase 1
- A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.CompletedNCT01490788Phase 1
- Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.CompletedNCT03168022Phase 1
- Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER CapsulesCompletedNCT03443960Phase 1
- 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia PatientsCompletedNCT02015234Phase 3
- Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type HeadacheCompletedNCT02423408Phase 2
- BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)CompletedNCT01903265Phase 2/3
- Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy VolunteersCompletedNCT02290379Phase 1
- Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy AdultsCompletedNCT01889173Phase 1
- Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy AdultsCompletedNCT01634412Phase 1
- Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy AdultsCompletedNCT01689259Phase 1